ClinicalTrials.gg
RecruitingNCT07286747CONCEPTUpdated Sep 16, 2026

Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)

A Phase 2 interventional study of controlled-ileal-release nicotinic acid as multiple dose 100 mg/day and controlled-ileal-release nicotinic acid as multiple dose 200 mg/day in Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), sponsored by University Hospital Schleswig-Holstein. Recruiting at 6 sites in Germany. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by University Hospital Schleswig-Holstein · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

The goal of this clinical trial is to prevent the change from prediabetes (a pre-stage of type 2 diabetes mellitus (T2DM)) to T2DM in participants with prediabetes using oral CIR-NA (a nicotinic acid formulation that is designed to be released after reaching the ileum) which targeted the gut microbiota. The main questions it aims to answer are:

  1. Is CIR-NA effective and does it prevent the change from prediabetes to T2DM?
  2. Is the safety of CIR-NA that was observed in the Phase I clinical trial confirmed in subjects with prediabetes?

Researchers will compare CIR-NA to a placebo (a look-alike substance that contains no drug) in terms of an extended safety evaluation including safety laboratory assessments, physical examination, vital signs and 12-lead ECG.

Participants will:

Take CIR-NA or a placebo every day for 26-weeks. Visit the clinic at week 1 and subsequently once every 4 weeks for checkups and tests.

Receive standardized lifestyle recommendations regarding nutrition and physical activity during the intervention.

Read the detailed description

The study is a multi-centre, randomised, double-blind, placebo-controlled trial evaluating the efficacy and safety of CIR-NA in participants with prediabetes. The trial includes a 26-week intervention period, which is expected to provide adequate time for prediabetes remission and a 4-week follow-up (FU) period.

A total of 390 male and female participants with a BMI of ≥ 20 kg/m² with prediabetes will be random-ised into three arms with 130 participants each in the CIR-NA (100 mg/d or 200 mg/d CIR-NA) and placebo groups. During the intervention, two indistinguishable tablets (CIR-NA and/or placebo) will be administered orally once daily. After screening and baseline assessment (including randomisation and IMP dispensing), 7 regular visits during treatment and one FU visit after 4 weeks are scheduled.

02

Conditions studied

  • Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
03

In context

Prediabetic State

918 studies on the registry are indexed under Prediabetic State; 232 are open to participants now.

This study's planned enrollment of 390 is above the median of 62 across 762 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

University Hospital Schleswig-Holstein is the lead sponsor of 163 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants ≥ 18 to \< 80 years of age (at the time of signing the ).
  2. ≥ 20 kg/m².
  3. Ability to understand and comply with the protocol.
  4. Signed written informed consent.
  5. Diagnosed prediabetes according to the current EASD/DDG guidelines. Prediabetes is present if at least one value is in the prediabetes range, but no value is in the T2DM range.
  6. Subgroup-specific: MASLD fibrosis score ≥ -1.455.

Exclusion criteria

Exclusion Criteria:

  1. Presence or a history of type 2 diabetes mellitus according to the current EASD/DDG guidelines.
  2. Participants with relevant medical conditions (based on evaluation of medical history and screening assessments), unstable and uncontrolled underlying diseases, e.g., hypothyroidism, asthma, or arterial hypertension, can be excluded per judgment of the Investigator.
  3. Renal impairment ( \<60 ml/min/1.73).
  4. Impairment of hepatic function (one or more of liver enzymes , aspartate transaminase and gamma glutamyl transferase [> 3-fold compared to normal range]).
  5. Current infection with or C.
  6. abnormal findings in medical history or screening assessments which, in the opinion of the Investigator, may put the participant at risk when participating in the trial or provide difficulties in interpreting the trial data.
  7. Current or history of except for completely resected basal cell carcinoma and squamous cell carcinoma of the skin.
  8. Alcohol or drug abuse within the last 2 years at the discretion of the Investigator.
  9. Subgroup-specific: Any circumstances which could contradict MRI and MRS imaging. For details, see Form (ICF) for additional examinations.
  10. Regular use of any prescribed or over-the-counter medication, food supplements or herbal preparations, which cannot be terminated 3 weeks before baseline and during the full duration of the trial. Pain medication (e.g., ibuprofen or paracetamol), topical allergy medicines, hormone replacement therapies and oral according to label are allowed. Medications in stable doses for controlling stable underlying diseases (see exclusion criterion 2) are also allowed per judgment of the Investigator.
  11. Use of antibiotics (systemic or gut-acting [non-absorbed]) within 8 weeks prior to the first dose of IMP.
  12. Long term use of higher doses of proton pump inhibitors, targeted H2-receptor antagonists or antacid formulations (i.e., doses equivalent to > 40 mg pantoprazole per day).
  13. Known towards any component of the CIR-NA or placebo tablets.
  14. Participation in a clinical trial (as defined in the clinical trial regulation (CTR)), currently or within 4 weeks prior to screening for this trial or intake of an IMP within the last 8 weeks or 5 half-lives (whichever is longer) prior to screening (or longer, if necessary, at the Investigator's discretion).
  15. Participants under legal supervision or guardianship, including participants who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  16. Participants who are dependent on the Investigator or the Sponsor.
  17. Pregnant or breastfeeding women.
  18. Women of (WoCBP) not using highly effective contraception till at least 1 month after last dosing of IMP.
  19. Male participants with female partners of childbearing potential who are not willing to use a highly effective contraception till at least 1 month after last dosing of IMP.
  20. Any other circumstances or medical conditions which could contradict a trial participation and lead the Investigator to assess the participant as unsuitable for trial participation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
390 participants (estimated)

Study arms

  • Active comparator
    CIR-NA 200

    CIR-NA 200 mg once daily

    Drug: controlled-ileal-release nicotinic acid as multiple dose 200 mg/day

  • Placebo comparator
    CIR-NA Placebo

    Placebo once daily

    Drug: controlled-ileal-release nicotinic acid as multiple dose placebo

  • Active comparator
    CIR-NA 100

    CIR-NA 100 mg once daily

    Drug: controlled-ileal-release nicotinic acid as multiple dose 100 mg/day

Interventions

  • Drugcontrolled-ileal-release nicotinic acid as multiple dose 100 mg/day

    130 participants will receive CIR-NA (100 mg/d). Additionally, all participants will receive standardized lifestyle recommendations regarding nutrition and physical activity.

    Also known as: CIR-NA 100 mg

  • Drugcontrolled-ileal-release nicotinic acid as multiple dose 200 mg/day

    130 participants will receive CIR-NA (200 mg/d). Additionally, all participants will receive standardized lifestyle recommendations regarding nutrition and physical activity.

    Also known as: CIR-NA 200 mg

  • Drugcontrolled-ileal-release nicotinic acid as multiple dose placebo

    130 participants will receive placebo. Additionally, all participants will receive standardized lifestyle recommendations regarding nutrition and physical activity.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Remission of prediabetes at week 26

    Remission of prediabetes at week 26 has been achieved when all values of HbA1c, fasting plasma glucose and 2-h-oGTT glucose are in the healthy range according to EASD/DDG guidelines.

    Time frame: up to 185 days

07

Study locations

2 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07286747
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Mar 3, 2026
Primary completion
May 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 16, 2026

Study contacts

Corinna Geisler, PhD
Contact
corinna.geisler@uksh.de
+4943150022446
Matthias Laudes, Prof. Dr.
Contact
matthias.laudes@uksh.de
+49 431 500 22217
Matthias Laudes, Prof. Dr.
principal investigator · University Medical Center Schleswig-Holstein, Campus Kiel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion